Top-Rated StocksTop-RatedNYSE:ENOV Enovis (ENOV) Stock Price, News & Analysis $48.08 +1.17 (+2.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$46.85▼$48.1750-Day Range$43.75▼$52.4152-Week Range$43.04▼$65.53Volume931,529 shsAverage Volume539,435 shsMarket Capitalization$2.64 billionP/E RatioN/ADividend YieldN/APrice Target$71.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enovis alerts: Email Address Enovis MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside48.6% Upside$71.44 Price TargetShort InterestHealthy8.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth17.94%From $2.62 to $3.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector267th out of 936 stocksSurgical Appliances & Supplies Industry8th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingEnovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageEnovis has only been the subject of 3 research reports in the past 90 days.Read more about Enovis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.10% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Enovis has recently decreased by 8.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnovis does not currently pay a dividend.Dividend GrowthEnovis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENOV. Previous Next 3.1 News and Social Media Coverage News SentimentEnovis has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Enovis this week, compared to 4 articles on an average week.Search Interest2 people have searched for ENOV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Enovis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enovis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Enovis is held by insiders.Percentage Held by Institutions98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enovis' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Enovis are expected to grow by 17.94% in the coming year, from $2.62 to $3.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enovis is -32.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enovis is -32.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnovis has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enovis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Enovis Stock (NYSE:ENOV)Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Read More ENOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENOV Stock News HeadlinesJuly 26 at 9:44 AM | msn.comEnovis Corporation Reschedules Earnings CallJuly 25 at 6:00 AM | globenewswire.comEnovis Announces Time Change for Second Quarter 2024 Results Conference CallJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 24 at 2:29 PM | finance.yahoo.comOrthopedic Implants Market size is set to grow by USD 12.54 billion from 2024-2028, High prevalence of osteoporosis boost the market, TechnavioJuly 23 at 8:10 PM | finance.yahoo.comInvestors in Enovis (NYSE:ENOV) have unfortunately lost 41% over the last three yearsJuly 21, 2024 | americanbankingnews.comEnovis Co. (NYSE:ENOV) Receives $71.44 Consensus Target Price from BrokeragesJuly 20, 2024 | bizjournals.comDenver-born data technology startup raises $8.8MJuly 16, 2024 | globenewswire.comEnovis to Host Second Quarter 2024 Results Conference Call on August 7thJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 15, 2024 | seekingalpha.comEnovis Languishing Despite Respectable PerformanceJuly 12, 2024 | globenewswire.comEnovis™ Releases AltiVate Reverse® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate Reverse®June 21, 2024 | benzinga.comTop 3 Health Care Stocks That Could Blast Off In JuneMay 17, 2024 | benzinga.comEnovis Stock (NYSE:ENOV), Quotes and News SummaryMay 12, 2024 | msn.comEnovis Corporation Announces Participation in Upcoming Investor ConferencesMay 10, 2024 | globenewswire.comEnovis to Participate in Upcoming Investor ConferencesMay 5, 2024 | seekingalpha.comEnovis: Solid Growth, But Unstable Financial FootingMay 3, 2024 | markets.businessinsider.comEnovis Poised for Growth: Strong Q1 Performance and Raised Guidance Support Buy RatingMay 3, 2024 | finance.yahoo.comEnovis Corp (ENOV) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic ...See More Headlines Receive ENOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNYSE:ENOV CUSIPN/A CIK1420800 Webwww.enovis.com Phone302-252-9160Fax301-323-9001Employees6,550Year FoundedN/APrice Target and Rating Average Stock Price Target$71.44 High Stock Price Target$82.00 Low Stock Price Target$53.00 Potential Upside/Downside+48.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E Ratio18.36 P/E GrowthN/ANet Income$-33,260,000.00 Net Margins-4.51% Pretax Margin-6.41% Return on Equity3.98% Return on Assets2.88% Debt Debt-to-Equity Ratio0.40 Current Ratio2.10 Quick Ratio1.03 Sales & Book Value Annual Sales$1.82 billion Price / Sales1.45 Cash Flow$6.70 per share Price / Cash Flow7.18 Book Value$62.66 per share Price / Book0.77Miscellaneous Outstanding Shares54,851,000Free Float53,535,000Market Cap$2.64 billion OptionableOptionable Beta1.92 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Matthew L. Trerotola (Age 57)CEO & Chairman Comp: $3.35MMr. Phillip Benjamin Berry (Age 45)Senior VP & CFO Comp: $1.08MMs. Patricia A. Lang (Age 65)Senior VP & Chief Human Resources Officer Comp: $1.01MMr. Daniel A. Pryor (Age 56)Executive Vice President of Strategy & Business Development Comp: $1.29MMr. Brady R. Shirley (Age 58)Executive Advisor & Director Comp: $2.02MMr. John Kleckner (Age 47)VP, Controller & Chief Accounting Officer Derek LeckowVice President of Investor RelationsMr. Bradley J. Tandy (Age 65)Senior VP & Chief Legal Officer Katie SweetVice President of Corporate CommunicationMr. Terry Ross (Age 54)Group President Prevention & Recovery More ExecutivesKey CompetitorsMSA SafetyNYSE:MSACadreNYSE:CDREEstablishment LabsNASDAQ:ESTAAvanos MedicalNYSE:AVNSJin Medical InternationalNASDAQ:ZJYLView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 14,196 shares on 7/26/2024Ownership: 1.812%Bank of New York Mellon CorpSold 3,113 shares on 7/26/2024Ownership: 0.770%AlphaCentric Advisors LLCBought 20,000 shares on 7/26/2024Ownership: 0.036%AMG National Trust BankBought 11,486 shares on 7/25/2024Ownership: 0.051%Institute for Wealth Management LLC.Bought 5,329 shares on 7/25/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions ENOV Stock Analysis - Frequently Asked Questions How have ENOV shares performed this year? Enovis' stock was trading at $56.02 at the start of the year. Since then, ENOV stock has decreased by 14.2% and is now trading at $48.08. View the best growth stocks for 2024 here. How were Enovis' earnings last quarter? Enovis Co. (NYSE:ENOV) posted its quarterly earnings results on Thursday, May, 2nd. The company reported $0.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.50. The firm's revenue for the quarter was up 27.0% compared to the same quarter last year. Who are Enovis' major shareholders? Enovis' top institutional shareholders include Allspring Global Investments Holdings LLC (1.81%), Artemis Investment Management LLP (0.91%), Bank of New York Mellon Corp (0.77%) and Tributary Capital Management LLC (0.75%). Insiders that own company stock include Matthew L Trerotola, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Phillip Benjamin (Ben) Berry, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner. View institutional ownership trends. How do I buy shares of Enovis? Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENOV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.